Pfizer's Revatio Fails To Improve Outcomes For Patients With Lung Disease: Study

Research published in NEJM suggests that Pfizer's Revatio (sildenafil) failed to meet its primary goal in a study involving patients with advanced idiopathic pulmonary fibrosis (IPF). However, the researchers noted that the improvements observed in secondary outcomes were "no doubt important to patients," given that no other treatments for the disease are currently available.